Three months ago we sat down with Dr. Beth Kolko, CEO of Shift Labs, to learn more about DripAssist Infusion Rate Monitor, a device that automates the calculation of IV infusion drip rates and total infusion volumes while also being able to alert a nurse when a drip rate changes or stops. At that time, DripAssist had already been FDA approved. At the end of last month, Shift Labs completed another regulatory milestone by securing CE Mark approval for DripAssist. Following this announcement, European Union member countries will now be able to benefit from accurate medication dosing as well as infusion time and cost savings that DripAssist has already been able to deliver in over 15 countries.
Tackling a different market than IV pumps, DripAssist is designed for secondary infusions and global markets where a lack of IV monitoring and the use of gravity IV administration sets pose challenges to accurate, reliable IV infusion. To solve these challenges, DripAssist allows the clinician to set the rate of a gravity IV drip while the technology automatically monitors drip rate and volume to ensure safe dosing. Designed with its target market in mind, the device does not require calibration, needs minimal training, and operates using one AA battery, making it incredibly portable.
“We look forward to introducing the DripAssist Infusion Rate Monitor to European Union member countries and Canada,” said Shift Labs CEO Beth Kolko. “We’re especially excited to provide our cost-effective, easy-to-use gravity IV monitoring solution to these forward-thinking markets that want to provide the most affordable and efficient care for patients.”
Product page: DripAssist…